Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holweg

Showing results (151-160 of 154) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 154 results.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2020
Urinary Leukotriene E<sub>4</sub> and Prostaglandin D<sub>2</sub> Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational StudyJohan Kolmert, Cristina Gómez, David Balgoma, et al.
Pageof 16

Showing results (151-160 of 154) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 154 results.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2020
Urinary Leukotriene E<sub>4</sub> and Prostaglandin D<sub>2</sub> Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational StudyJohan Kolmert, Cristina Gómez, David Balgoma, et al.
Pageof 16